汤臣倍健股份有限公司 关于选举第六届董事会职工董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 汤臣倍健股份有限公司（以下简称"公司"）于 2025 年 8 月 25 日召开 2025 年第一次临时股东会，审议通过了《关于修订<公司章程>的议案》。根据新修订 的《公司章程》，公司董事会由 7 名董事组成，其中包含 1 名职工董事。 结合公司治理结构调整实际情况，公司于同日召开职工代表大会，与会职工 代表一致同意选举汤晖先生（简历详见附件）为公司第六届董事会职工董事，任 期自职工代表大会审议通过之日起至公司第六届董事会任期届满之日止。 汤晖先生符合《中华人民共和国公司法》、《深圳证券交易所上市公司自律监 管指引第 2 号——创业板上市公司规范运作》及《公司章程》规定的有关职工董 事的任职资格。本次职工董事选举完成后，公司第六届董事会成员构成未发生变 化，兼任公司高级管理人员以及由职工代表担任的董事人数总计未超过公司董事 总数的二分之一。 特此公告。 汤臣倍健股份有限公司 董 事 会 证券代码：300146 证券简称：汤臣倍健 公告编号：2025-043 ...

北 京 上 海 深 圳 杭 州 广 州 昆 明 天 津 成 都 宁 波 福 州 西 安 南 京 南 宁 济 南 重 庆 苏 州 长 沙 太 原 武 汉 贵 阳 乌 鲁 木 齐 郑 州 石 家 庄 合 肥 海 南 青 岛 南 昌 大 连 银 川 拉 孜 香 港 巴 黎 马 德 里 斯 德 哥 尔 摩 纽 约 马 来 西 亚 柬 埔 寨 乌 兹 别 克 斯 坦 广州市天河区华夏路 32 号太平洋金融大厦 19 楼 邮编：510620 电话：(+86)(20) 3879 9346 、3879 9348 传真：(+86)(20) 3879 9348-200 国浩律师(广州)事务所 关于汤臣倍健股份有限公司 2025 年第一次临时股东会的法律意见 汤臣倍健股份有限公司： 根据中国证券监督管理委员会发布的《上市公司股东会规则》(以下简称《股 东会规则》)的要求，国浩律师(广州)事务所(以下简称"本所")接受汤臣倍健 股份有限公司(以下简称"汤臣倍健"或"公司")的委托，指派李彩霞、林嘉豪 律师(以下简称"本所律师")出席汤臣倍健 2025 年第一次临时股东会(以下简称 "本次股东会")，对本次股东会的召集与召开程序、出席 ...

Core Viewpoint - The health supplement market in China is experiencing significant challenges, as evidenced by the poor performance of leading companies like汤臣倍健, which has seen substantial declines in revenue and profit, indicating a shift in consumer behavior and market dynamics [2][4][6]. Company Performance -汤臣倍健 reported a revenue of 35.32 billion yuan in the first half of 2025, a year-on-year decrease of 23.43%, with a net profit of 7.37 billion yuan, down 17.34% [2]. - For the entire year of 2024,汤臣倍健's revenue was 68.38 billion yuan, a decline of 27.3%, and net profit fell by 62.62% to 6.53 billion yuan, marking the largest drop since its listing [5][6]. - The company's market capitalization has decreased from a peak of 600 billion yuan to approximately 209 billion yuan, resulting in a loss of nearly 400 billion yuan in value [6]. Market Dynamics - The health supplement industry is not in decline; rather, it is evolving, with younger consumers adopting "punk health" trends, leading to a shift in purchasing behavior [3][9]. - The market for health supplements grew to 604.1 billion yuan in the first half of 2025, reflecting a 16.2% increase, with specific categories like bone health and oral beauty products driving growth [19]. Brand Strategy and Challenges -汤臣倍健's traditional branding and marketing strategies are becoming outdated, as the company struggles to connect with younger consumers [7][11]. - The company has seen a significant reduction in its domestic distributor network, with 597 distributors remaining as of June 2025, down over 340 from the end of 2023 [7]. - Despite launching new products,汤臣倍健 has failed to establish a strong online presence or effectively market to younger demographics, resulting in stagnant sales for its core products [8][11]. Competitive Landscape - Newer brands like诺特兰德, Swisse, and万益蓝 are successfully targeting younger consumers with innovative marketing strategies and product offerings, capturing significant market share [10][11]. - These brands leverage social media and influencer marketing to resonate with younger audiences, contrasting with汤臣倍健's more traditional approach [10][11].

（编辑 楚丽君） 证券日报网讯 8月20日晚间，汤臣倍健发布公告称，截至2025年8月20日，本次回购期限届满，回购方 案已实施完毕。本次实际回购时间区间为2025年2月5日至2025年7月31日。公司累计通过回购专用账户 以集中竞价交易方式回购9，168，400股，占公司总股本的0.5390%。 ...

Core Viewpoint - The health supplement market in China is experiencing significant challenges, as evidenced by the poor performance of leading companies like汤臣倍健, which has seen substantial declines in revenue and profit. However, the overall market is still growing, driven by younger consumers seeking health products, indicating a shift in consumer behavior and preferences [3][4][32]. Group 1: Company Performance -汤臣倍健 reported a revenue of 35.32 billion yuan in the first half of 2025, a year-on-year decline of 23.43%, with a net profit of 7.37 billion yuan, down 17.34% [3]. - For the entire year of 2024,汤臣倍健's revenue was 68.38 billion yuan, a decrease of 27.3%, and net profit fell by 62.62%, marking the largest decline since its listing [3][9]. - The company's market capitalization has dropped from a peak of 600 billion yuan to approximately 209 billion yuan, resulting in a loss of nearly 400 billion yuan in value [3][9]. Group 2: Market Trends - The health supplement industry is not in decline; rather, it is evolving, with younger consumers engaging in "punk health" practices, leading to increased spending on health products [5][14]. - Data from 2023 indicates a 255% increase in consumption of uric acid monitoring products among consumers born in the 1990s, with 30% of their spending on immune-boosting supplements [15]. - Brands targeting younger demographics, such as诺特兰德 and Swisse, are thriving by employing innovative marketing strategies and product offerings [16][19]. Group 3: Challenges and Strategies -汤臣倍健's traditional marketing and distribution strategies have become outdated, leading to a significant drop in sales across its product lines [10][11]. - The company has reduced its advertising and marketing expenses, which has further contributed to declining revenues and profits [11]. - Despite launching new products,汤臣倍健 has struggled to capture the younger market, missing out on the e-commerce boom and innovative marketing tactics that competitors have successfully utilized [12][17]. Group 4: Historical Context - The Chinese health supplement market has evolved over nearly 40 years, with discussions around "intelligence tax" continuing as long as consumers fear aging, death, and loss of beauty [21][32]. - The market saw significant growth in the 1990s, but regulatory changes led to a downturn, from which汤臣倍健 and other second-generation companies emerged to dominate the market [31][32]. - Recent data shows that the health supplement market generated sales of 604.1 billion yuan in the first half of 2025, reflecting a growth of 16.2%, with specific categories like sleep management products growing by 53.1% [32].

Group 1 - The revenue composition of Tongchen Baijian for the first half of 2025 is as follows: Other products account for 38.02%, capsules 27.84%, tablets 20.38%, and powders 13.76% [1] - Tongchen Baijian announced the completion of its share repurchase plan, which was executed from February 5, 2025, to July 31, 2025 [3] - The company repurchased a total of 9,168,400 shares, representing 0.5390% of its total share capital, with a total expenditure of RMB 105,201,465.00 [3]

格隆汇8月20日丨汤臣倍健(300146.SZ)公布，截至2025年8月20日，本次回购期限届满，回购方案已实 施完毕。本次实际回购时间区间为2025年2月5日至2025年7月31日。公司累计通过回购专用账户以集中 竞价交易方式回购916.84万股，占公司总股本的0.5390%，最高成交价为11.95元/股，最低成交价为 10.78元/股，支付总金额为人民币1.05亿元(不含交易费用)。 ...

证券代码：300146 证券简称：汤臣倍健 公告编号：2025-041 汤臣倍健股份有限公司 关于股份回购实施结果暨股份变动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 汤臣倍健股份有限公司（以下简称"公司"）分别于 2024 年 8 月 4 日、8 月 21 日、2025 年 2 月 25 日召开第六届董事会第十次会议、2024 年第二次临时股 东大会及第六届董事会第十四次会议，审议通过了《关于回购公司股份方案的议 案》《关于调整回购股份资金来源的议案》，同意公司使用自有资金及自筹资金以 集中竞价交易方式回购股份，用于注销并减少注册资本。本次回购资金总额不低 于人民币 10,000 万元（含），不超过人民币 20,000 万元（含），回购价格不超过 人民币 20 元/股（含），回购期限为自股东大会审议通过回购股份方案之日起不 超过 12 个月。具体内容详见公司分别于 2024 年 8 月 6 日、2025 年 2 月 26 日刊 登在巨潮资讯网的《关于回购股份方案的公告》《关于取得金融机构股票回购贷 款承诺函的公告》。 截至本公告披露日，公司本次回购 ...

Market Overview - On August 20, the food processing sector rose by 0.77% compared to the previous trading day, with Xianle Health leading the gains [1] - The Shanghai Composite Index closed at 3766.21, up 1.04%, while the Shenzhen Component Index closed at 11926.74, up 0.89% [1] Key Performers - Xianle Health (300791) closed at 24.94, with a gain of 5.23% and a trading volume of 121,000 shares, amounting to a transaction value of 297 million yuan [1] - Gai Shi Food (836826) closed at 13.29, up 4.24%, with a trading volume of 126,200 shares and a transaction value of 167 million yuan [1] - Huifa Food (603536) closed at 9.94, increasing by 3.54%, with a trading volume of 200,800 shares and a transaction value of 198 million yuan [1] Fund Flow Analysis - The food processing sector saw a net inflow of 44.04 million yuan from institutional investors, while retail investors experienced a net outflow of 29.46 million yuan [2] - Major stocks like Xiwang Food (000639) had a net inflow of 22.14 million yuan from institutional investors, while Xianle Health (300791) saw a net inflow of 19.85 million yuan [3] Individual Stock Performance - Xianle Health had a net inflow of 1,985,270 yuan from institutional investors, with a retail net outflow of 3,655,300 yuan [3] - Xiwang Food experienced a net inflow of 2,214,520 yuan from institutional investors, while retail investors had a net outflow of 821,620 yuan [3] - Anji Food (603345) had a net inflow of 1,344,120 yuan from institutional investors, with a retail net outflow of 886,470 yuan [3]

8月19日汤臣倍健大宗交易一览 | | 成交金 | | 相对当 | | | | --- | --- | --- | --- | --- | --- | | 成交量 | 额 | 成交价 | 日 | | | | （万 | （万 | 格 | 收盘折 | 买方营业部 | 卖方营业部 | | 股） | 元） | （元） | 溢价 | | | | | | | （%） | | | | 17.62 | 260.42 | 14.78 | 20.36 | 招商证券股份有限公司苏州华池街 | 招商证券股份有限公司苏州华池街 | | | | | | 证券营业部 | 证券营业部 | （原标题：汤臣倍健发生大宗交易 成交溢价率20.36%） 汤臣倍健8月19日大宗交易平台出现一笔成交，成交量17.62万股，成交金额260.42万元，大宗交易成交 价为14.78元，相对今日收盘价溢价20.36%。该笔交易的买方营业部为招商证券股份有限公司苏州华池 街证券营业部，卖方营业部为招商证券股份有限公司苏州华池街证券营业部。 证券时报•数据宝统计显示，汤臣倍健今日收盘价为12.28元，下跌0.49%，日换手率为1.84%，成交额为 2.57亿元，全 ...